5' CpG island methylation analysis identifies the MAGE-A1 and MAGE-A3 genes as potential markers of HCC

Clinical Biochemistry
Geng QiuYunshao He

Abstract

The change in DNA methylation patterns can be used to distinguish between normal and cancer cells. The aim of the present study was to examine the 5' CpG island methylation patterns of the cancer-testis antigen (CT antigen) gene family, MAGE-As, in hepatocellular carcinoma (HCC), and to develop the DNA demethylation pattern as a novel tumor biomarker. We used bisulfite-sequencing PCR (BSP) to map the methylation status of the CpG site among the promoter of the MAGE-A gene family in several HCC cell lines including Hep G2, BEL7402, BEL7404, and BEL7407, and normal peripheral blood white blood cells (WBCs). According to differences of the methylation pattern between HCC cell lines and the control, methylation-special PCRs (MSP) have been developed. The developed MSPs were used to detect the paraffin-embedded slices that were pathologically diagnosed as HCC, hepatocirrhosis, hepatitis, and healthy. We found that several CpG sites among the MAGE-A1 and MAGE-A3 promoters have different methylation patterns in the HCC cell lines as compared to those in normal WBCs. Two sets of MSP primers were designed to distinguish the HCC genomic DNA and normal control cell genomic DNA as novel tumor biomarkers, and the biomarkers were validated o...Continue Reading

References

Dec 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·F Antequera, A Bird
Aug 11, 1994·Nucleic Acids Research·S J ClarkM Frommer
Sep 3, 1996·Proceedings of the National Academy of Sciences of the United States of America·J G HermanS B Baylin
Oct 31, 2001·Seminars in Oncology·A Monto, T L Wright
Dec 26, 2001·Human Molecular Genetics·M EstellerJ G Herman
Nov 9, 2002·Bioinformatics·Long-Cheng Li, Rajvir Dahiya
Apr 3, 2003·Nature Reviews. Cancer·Peter W Laird
May 2, 2003·Annals of the New York Academy of Sciences·Maxwell P Lee
Jun 6, 2003·The Lancet Oncology·Manel Esteller
Oct 7, 2003·Oncogene·Richard L Momparler
Oct 31, 2003·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Manel Esteller
Nov 25, 2003·The New England Journal of Medicine·James G Herman, Stephen B Baylin
Feb 5, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Andreas WidschwendterMartin Widschwendter
May 8, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Takao TakahashiAdi F Gazdar
May 28, 2004·Nature·Gerda EggerPeter A Jones
Jul 21, 2004·Trends in Genetics : TIG·Hans T BjornssonAndrew P Feinberg
Oct 12, 2004·European Urology·Rui Henrique, Carmen Jerónimo
Dec 2, 2004·Nature Reviews. Cancer·Jean-Pierre Issa
Jan 18, 2005·Nucleic Acids Research·Gábor E TusnádyTamás Arányi
Mar 11, 2005·Best Practice & Research. Clinical Gastroenterology·Man-Fung Yuen, Ching-Lung Lai

❮ Previous
Next ❯

Citations

Nov 26, 2008·BMC Medical Genomics·Maté OngenaertEd Schuuring
Feb 26, 2008·Expert Opinion on Biological Therapy·Viktoria N Evdokimova, Lisa H Butterfield
Jul 18, 2009·International Journal of Cancer. Journal International Du Cancer·Pedro A Andrade FilhoRobert L Ferris
Nov 16, 2010·Developmental Cell·María Berdasco, Manel Esteller
Feb 24, 2019·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Xiaojuan ShiYi Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Adrenocortical Carcinoma

Hepatocellular carcinoma is the most common type of primary liver cancer and frequently occurs in individuals with chronic liver diseases like cirrhosis. Here is the latest research.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.